Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masato Nakamura

Showing results (551-560 of 709) with videos related to

Pageof 71
Sort By:
Targeted Oncology|October 25, 2017
CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal CancerYu Sunakawa, Akihito Tsuji, Tadamichi Denda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2004
Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular CarcinomaTameyoshi Yamamoto, Hiroaki Nagano, Masato Sakon, et al.
Oncology Reports|February 9, 2006
Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significanceDi Tang, Hiroaki Nagano, Hirofumi Yamamoto, et al.
Oncotarget|May 4, 2018
A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11Hironaga Satake, Yu Sunakawa, Yuji Miyamoto, et al.
Psychiatry Research|August 8, 2013
The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophreniaKotaro Hatta, Hiroshi Takebayashi, Yasuhiko Sudo, et al.
Journal of Cardiology|January 28, 2014
Japanese and non-Japanese patient outcomes in the PLATINUM randomized trial comparing the PROMUS Element and XIENCE V everolimus-eluting stentsShigeru Saito, Nobuhisa Hagiwara, Atsushi Seki, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|December 26, 2006
Impact of cutting balloon angioplasty (CBA) prior to bare metal stenting on restenosisYukio Ozaki, Tetsu Yamaguchi, Takahiko Suzuki, et al.
Anticancer Research|April 30, 2022
Initial Safety Analysis of CapeOx for Elderly Patients With Advanced Gastric Cancer Patients: A Phase II TrialKeisho Chin, Daisuke Takahari, Ryohei Kawabata, et al.
Atherosclerosis|March 23, 2017
Impact of attenuated-signal plaque observed by intravascular ultrasound on vessel response after drug-eluting stent implantationHideki Kitahara, Katsuhisa Waseda, Kenji Sakamoto, et al.
Oncotarget|April 18, 2018
Successful retreatment with grazoprevir and elbasvir for patients infected with hepatitis C virus genotype 1b, who discontinued prior treatment with NS5A inhibitor-including regimens due to adverse eventsTatsuo Kanda, Shin Yasui, Masato Nakamura, et al.
Pageof 71

Showing results (551-560 of 709) with videos related to

Sort By:
Pageof 71
Targeted Oncology|October 25, 2017
CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal CancerYu Sunakawa, Akihito Tsuji, Tadamichi Denda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2004
Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular CarcinomaTameyoshi Yamamoto, Hiroaki Nagano, Masato Sakon, et al.
Oncology Reports|February 9, 2006
Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significanceDi Tang, Hiroaki Nagano, Hirofumi Yamamoto, et al.
Oncotarget|May 4, 2018
A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11Hironaga Satake, Yu Sunakawa, Yuji Miyamoto, et al.
Psychiatry Research|August 8, 2013
The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophreniaKotaro Hatta, Hiroshi Takebayashi, Yasuhiko Sudo, et al.
Journal of Cardiology|January 28, 2014
Japanese and non-Japanese patient outcomes in the PLATINUM randomized trial comparing the PROMUS Element and XIENCE V everolimus-eluting stentsShigeru Saito, Nobuhisa Hagiwara, Atsushi Seki, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|December 26, 2006
Impact of cutting balloon angioplasty (CBA) prior to bare metal stenting on restenosisYukio Ozaki, Tetsu Yamaguchi, Takahiko Suzuki, et al.
Anticancer Research|April 30, 2022
Initial Safety Analysis of CapeOx for Elderly Patients With Advanced Gastric Cancer Patients: A Phase II TrialKeisho Chin, Daisuke Takahari, Ryohei Kawabata, et al.
Atherosclerosis|March 23, 2017
Impact of attenuated-signal plaque observed by intravascular ultrasound on vessel response after drug-eluting stent implantationHideki Kitahara, Katsuhisa Waseda, Kenji Sakamoto, et al.
Oncotarget|April 18, 2018
Successful retreatment with grazoprevir and elbasvir for patients infected with hepatitis C virus genotype 1b, who discontinued prior treatment with NS5A inhibitor-including regimens due to adverse eventsTatsuo Kanda, Shin Yasui, Masato Nakamura, et al.
Pageof 71